Why the study?
Does losartan improve LVH regression in hypertensive patients with ECG LVH compared to atenolol?
Does losartan improve LVH regression in hypertensive patients with ECG LVH compared to atenolol?
Losartan-based antihypertensive therapy demonstrates superior efficacy over atenolol for reversing left ventricular hypertrophy, a key marker of hypertensive target organ damage.
Answers are grounded in this paper and cite their sources.
Losartan may be preferred over atenolol for LVH regression in hypertension; confirms ARB benefit on hypertensive target-organ damage.
Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment. Thus, angiotensin receptor antagonism by losartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.
No takes yet. Share an insight, caveat, or question.
Devereux et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: